

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | IGF-1R ↓ ↑ | Insulin Receptor ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMS-536924 |
++
IGF-1R, IC50: 100 nM |
+++
Insulin Receptor, IC50: 73 nM |
MEK,FAK | 98% | |||||||||||||||
| GSK1904529A |
+++
IGF-1R, IC50: 27 nM |
+++
Insulin Receptor, IC50: 25 nM |
98+% | ||||||||||||||||
| Picropodophyllin |
++++
IGF-1R, IC50: 1 nM |
99%+ | |||||||||||||||||
| NVP-AEW541 |
++
IGF-1R, IC50: 0.15 μM |
++
Insulin Receptor, IC50: 0.14 μM |
FLT3 | 99%+ | |||||||||||||||
| NVP-ADW742 |
+
IGF-1R, IC50: 0.17 μM |
98% | |||||||||||||||||
| GSK1838705A |
+++
IGF-1R, IC50: 2 nM |
++++
Insulin Receptor, IC50: 1.6 nM |
ALK | 98% | |||||||||||||||
| BMS-754807 |
++++
IGF-1R, IC50: 1.8 nM |
++++
Insulin Receptor, IC50: 1.7 nM |
99%+ | ||||||||||||||||
| Linsitinib |
+++
IGF-1R, IC50: 35 nM |
++
Insulin Receptor, IC50: 75 nM |
99%+ | ||||||||||||||||
| AG1024 |
+
IGF-1R, IC50: 7 μM |
+
Insulin Receptor, IC50: 57 μM |
98% | ||||||||||||||||
| PQ401 |
+
IGF-1R, IC50: <1 μM |
99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM. |
| Concentration | Treated Time | Description | References | |
| CD34+ AML cells | 1 to 7 µM | 14 days | BMS-536924 inhibited leukemic colony formation in these samples | Cancer Res. 2009 Oct 1;69(19):7635-43. |
| CD8-IGF-IR-MCF10A | 1 µM | 24 hours | BMS-536924 completely inhibited the proliferation of CD8-IGF-IR-MCF10A cells, restored apical-basal polarity, and enhanced apoptosis, resulting in a partial phenotypic reversion to normal acini. | Clin Cancer Res. 2009 Jan 1;15(1):226-37. |
| MCF7 cells | 1 µM | 4 days | BMS-536924 inhibited the proliferation of MCF7 cells and resulted in the formation of hollow polarized lumen. | Clin Cancer Res. 2009 Jan 1;15(1):226-37. |
| MCF-7 cells | 10 µM | 48 hours | IGFBP-5 overexpression in MCF-7 cells conferred resistance to BMS-536924 | Clin Cancer Res. 2012 Mar 15;18(6):1808-17. |
| SCLC cells | 100 nM | 48 hours | BMS-536924 suppresses IGF1R-induced phosphorylation of PI3K/AKT, thereby repressing SCLC cell proliferation and differentiation. | Mol Cancer. 2022 Jun 6;21(1):123. |
| PC9, PFR3, PFR5 | 1 µM | 6 hours | To restore sensitivity to EGFR TKIs in drug-resistant cells. | Cancer Res. 2013 Jan 15;73(2):834-43. |
| Ba/F3 cells | 19 nM | 72 hours | BMS-536924 selectively inhibited the proliferation of CD74-NTRK1 transformed Ba/F3 cells with an IC50 of 19 nM, while the IC50 for parental cells was > 470 nM. | Clin Cancer Res. 2017 Jan 1;23(1):204-213. |
| CUTO-3 cells | 34 nM | 72 hours | BMS-536924 inhibited the proliferation of CUTO-3 cells with an IC50 of 34 nM. | Clin Cancer Res. 2017 Jan 1;23(1):204-213. |
| MCF-7R4 cells | 10 µM | IGFBP-5 knockdown decreased BMS-536924 resistance in MCF-7R4 cells | Clin Cancer Res. 2012 Mar 15;18(6):1808-17. | |
| Administration | Dosage | Frequency | Description | References | ||
| Nude mice | SCLC xenograft model | Oral gavage | 100 mg/kg | Once daily for 16 consecutive days | BMS-536924 significantly enhanced the suppressive effects of circVAPA knockdown on SCLC tumor growth, suggesting that BMS-536924 and circVAPA depletion might achieve a potential synergistic effect in the treatment of SCLC. | Mol Cancer. 2022 Jun 6;21(1):123. |
| Nude mice | CD8-IGF-IR-MCF10A xenograft model | Oral | 100 mg/kg/day | Daily for 2 weeks | BMS-536924 significantly reduced the volume of xenograft tumors by an average of 76%. | Clin Cancer Res. 2009 Jan 1;15(1):226-37. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.08mL 0.42mL 0.21mL |
10.42mL 2.08mL 1.04mL |
20.84mL 4.17mL 2.08mL |
|
| CAS号 | 468740-43-4 |
| 分子式 | C25H26ClN5O3 |
| 分子量 | 479.96 |
| SMILES Code | O=C1C(C2=NC3=C(C)C=C(N4CCOCC4)C=C3N2)=C(NC[C@H](C5=CC=CC(Cl)=C5)O)C=CN1 |
| MDL No. | MFCD14635360 |
| 别名 | CS-0117 |
| 运输 | 蓝冰 |
| InChI Key | ZWVZORIKUNOTCS-OAQYLSRUSA-N |
| Pubchem ID | 135440466 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 9 mg/mL(18.75 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1